分析师： 叶寅 投资咨询资格编号:S1060514100001 邮箱：YEYIN757@PINGAN.COM.CN 韩盟盟 投资咨询资格编号:S1060519060002 邮箱：HANMENGMENG005@PINGAN.COM.CN 张梦鸽 投资咨询资格编号:S1060525070003 邮箱：ZHANGMENGGE752@PINGAN.COM.CN 2025年11月25日 请务必阅读正文后免责条款 行业观点 证券研究报告 海外MNC动态跟踪系列（十八） 艾伯维发布2025Q3财报：自免双星销售强劲 医药 强于大市（维持） 平安证券研究所 医药团队 • 监管批准：1）Rinvoq 治疗白癜风；2）Venclexta 治疗高危骨髓增生异常综合征（MDS）；3）Pivekimab Sunirine 用于 BPDCN（母细胞性浆细 胞样树突细胞肿瘤）；4）Tavapadon用于帕金森病；5）BoNT/E治疗眉间纹（Glabellar Lines） • 监管提交：1）Rinvoq 治疗白癜风；2）Rinvoq 治疗斑秃（Alopecia Areata）；3）Rinvoq 治疗化脓性汗腺炎（Hidradenitis ...

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.I’m talking about corporate spin-offs, those unloved stepchildren distributed to shareholders who often sell them without a second thought.They have beaten the market for 30 years with remarkable consistency.Save 50% On Benzinga Pro This Black FridayThis Black Friday, step up to the same tools used by professionals ...

Accessibility StatementSkip Navigation AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma NORTH CHICAGO, Ill., Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time. A live audio webcast of the presentation will be accessible thro ...

For Immediate ReleasesChicago, IL – November 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan Chase & Co. (JPM) , Netflix, Inc. (NFLX) , AbbVie Inc. (ABBV) and Ohio Valley Banc Corp. (OVBC) . Here are highlights from Monday’s Analyst Blog:Top Research Reports for JPMorgan Chase, Netflix and AbbVieThe Z ...

Core Insights - The integration of Artificial Intelligence (AI) in the U.S. healthcare industry has significantly increased, with 79% of healthcare organizations utilizing AI technology as of March 2024 [1] Group 1: AI Integration in Healthcare - AI is being integrated across various industries, including healthcare, with notable partnerships between pharmaceutical companies and AI tech firms [2] - Collaborations are expected to accelerate drug discovery, streamline clinical trials, and automate administrative tasks, potentially saving billions and enhancing operational efficiency [3][9] Group 2: Notable Pharma-Tech Collaborations - Eli Lilly is partnering with NVIDIA to create an "AI Factory" aimed at accelerating drug discovery by compressing decades of research into accessible intelligence [5] - Johnson & Johnson has been collaborating with NVIDIA to enhance surgical decision-making and training through real-time AI analysis in operating rooms [6] - AbbVie utilizes Palantir's Foundry platform for data management, which unifies data sources and streamlines clinical trial data, boosting operational efficiency [8] Group 3: Market Potential and Investment Opportunities - The global AI in healthcare market is projected to grow from $26.57 billion in 2024 to $505.59 billion by 2033, with a CAGR of 38.81% [10] - Vanguard Health Care ETF (VHT) has assets worth $16.2 billion, with significant weightage in Eli Lilly, AbbVie, and Johnson & Johnson, and has surged 12.3% year to date [11] - Health Care Select Sector SPDR ETF (XLV) has assets under management of $39.01 billion, also featuring major pharmaceutical companies, and has increased by 11.6% year to date [12][13]

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 9 unusual trades.Delving into the details, we found 11% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $326,123, and 5 were calls, valued at $230,186.Expected Price MovementsBased on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - Eli Lilly's revenue increased by 52% year-on-year in Q3 2025, driven by GLP-1 drugs, with Tirzepatide's quarterly revenue exceeding $10 billion for the first time, showing a 131% year-on-year growth [4] - Novo Nordisk faced intensified competition in the weight loss drug market, leading to a modest revenue growth of 1% for Ozempic and 6% for Wegovy in Q3 2025, prompting a downward revision of its annual performance guidance [4] - A total of 11 out of 16 companies in the report raised their revenue and/or net profit/EPS forecasts for the year, primarily due to better-than-expected sales of new products [4] Summary by Sections 1. Q3 2025 Performance Review - Eli Lilly's Q3 revenue reached $17.6 billion, with a 62% increase in sales volume, while net prices decreased by 10% [12] - Novo Nordisk's sales revenue for Q3 was 75 billion Danish Kroner, with a net profit decline of 27% [13] - JNJ's pharmaceutical segment achieved revenue of $15.6 billion, with significant contributions from oncology and neurology products [14] - AbbVie reported global sales of $15.8 billion, with notable growth in immunology and neurology sectors [15] - Gilead's revenue for Q3 was $7.3 billion, with a 4% increase in HIV product sales [16] 2. MNC Product Performance in the U.S. Market - The median time for MNC products to reach peak sales in the U.S. market is approximately 8 years, with first-in-class (FIC) products achieving this in about 7 years [4] 3. Revenue and Guidance Adjustments - Eli Lilly raised its full-year revenue guidance from $60-62 billion to $63-63.5 billion [12] - Novo Nordisk revised its revenue growth forecast down from 8%-14% to 8%-11% [13] - JNJ increased its full-year revenue guidance from $93.2-93.6 billion to $93.5-93.9 billion [14]

Core Viewpoint - The article emphasizes the importance of dividend stocks as a reliable investment strategy during market volatility, highlighting AbbVie and Realty Income as two strong candidates for income-focused investors [3][5][13]. Company Summaries AbbVie (ABBV) - AbbVie has shown significant stock performance, with a year-to-date increase of 36% and a 187% rise over the last five years [4][8]. - The company offers an annual dividend of $6.92, resulting in a yield of 2.96%, making it attractive for income investors [7][8]. - AbbVie maintains a strong cash flow supported by a diversified drug pipeline in immunology, neuroscience, and oncology, which enhances its stability during market downturns [9][14]. Realty Income (O) - Realty Income, known as "The Monthly Dividend Company," has raised its dividend for 21 consecutive years, showcasing its reliability [10][11]. - The current dividend yield stands at 5.64%, with annual payouts of $3.21, appealing to investors seeking consistent income [11]. - The company's business model, based on long-term net lease agreements, provides predictable revenue and resilience against economic downturns [11][12]. Investment Strategy - Both AbbVie and Realty Income operate in different sectors but together create a balanced foundation for investors looking for passive income [13][14]. - AbbVie provides exposure to the healthcare sector with strong cash generation, while Realty Income offers monthly income through reliable long-term contracts [14].

Key Takeaways AbbVie beat Q3 estimates and raised 2025 guidance despite a post-earnings stock dip.Strong Skyrizi and Rinvoq sales helped ABBV offset Humira erosion and drive ex-Humira growth.Strong Skyrizi and Rinvoq sales helped ABBV offset Humira erosion and drive ex-Humira growth.AbbVie’s (ABBV) reported third-quarter 2025 results on Oct. 31, before market open. The company beat estimates for both earnings and sales. While sales rose 9.1% year over year, earnings declined 38% due to costs related to acqu ...

Sector Rotation: The AI sector appears ripe for profit-taking, with a majority of tech stocks now trading below their 20-day moving averages. In contrast, healthcare is seeing inflows not observed since early 2021. As investors seek stability, healthcare's reputation as a defensive play could fuel a longer-term rally.Attractive Valuations and Strong Earnings: Healthcare has become undervalued, especially compared to the nosebleed valuations tech companies have received. Healthcare trades at just 16 times fo ...